HDAC9 and melanoma: Based on the mechanistic discoveries of epigenetic regulation of melanoma immunology, multiple clinical trials have been conducted to verify the effect and safety of the combined therapy with both immune checkpoint blockade and epigenetics-targeting drugs, particularly with DNA hypomethylating agents and HDAC inhibition agents that have been documented to play prominent roles in the regulation of antitumor immunity in melanoma.